Literature DB >> 9633881

Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes.

M Hou1, P O Andersson, D Stockelberg, U H Mellqvist, B Ridell, H Wadenvik.   

Abstract

To evaluate the diagnostic value of thrombopoietin (TPO, c-mpl ligand) measurements, and clarify the regulatory mechanisms of TPO in normal and in thrombocytopenic conditions, the plasma TPO concentration was determined in normal individuals (n = 20), umbilical cord blood (n = 40), chronic idiopathic thrombocytopenic purpura (ITP; n = 16), in severe aplastic anaemia (SAA; n = 3), chemotherapy-induced bone marrow hypoplasia (n = 10), myelodysplastic syndrome (MDS; n = 11), and sequentially during peripheral blood progenitor cell transplantation (n = 7). A commercially available ELISA and EDTA-plasma samples were used for the analysis. The plasma TPO concentration in the normals and umbilical cord blood were 52 +/- 12 pg/ml and 66 +/- 12 pg/ml, respectively. The corresponding values in patients with SAA and chemotherapy-induced bone marrow hypoplasia were 1514 +/- 336 pg/ml and 1950 +/- 1684 pg/ml, respectively, and the TPO concentration, measured sequentially after myeloablative chemotherapy and peripheral blood progenitor cell transplantation, was inversely related to the platelet count. In contrast, the plasma TPO recorded in patients with ITP (64 +/- 20 pg/ml) and MDS (68 +/- 23 pg/ml) were only slightly higher than normal levels. In conclusion, TPO levels were significantly elevated in patients in which bone marrow megakaryocytes and platelets in circulation were markedly reduced, whereas TPO levels were normal in ITP patients, and only slightly increased in the MDS patients. These latter patients displayed a preserved number of megakaryocytes in bone marrow biopsies. Our data support the suggestion that megakaryocyte mass affects the plasma TPO concentration. In thrombocytopenic patients a substantially increased plasma TPO implies deficient megakaryocyte numbers. However, TPO measurements do not distinguish between ITP and thrombocytopenia due to dysmegakaryopoiesis, as seen in MDS patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633881     DOI: 10.1046/j.1365-2141.1998.00747.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation).

Authors:  Patrizia Noris; Silverio Perrotta; Roberta Bottega; Alessandro Pecci; Federica Melazzini; Elisa Civaschi; Sabina Russo; Silvana Magrin; Giuseppe Loffredo; Veronica Di Salvo; Giovanna Russo; Maddalena Casale; Daniela De Rocco; Claudio Grignani; Marco Cattaneo; Carlo Baronci; Alfredo Dragani; Veronica Albano; Momcilo Jankovic; Saverio Scianguetta; Anna Savoia; Carlo L Balduini
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Authors:  Sagar Lonial; Edmund K Waller; Paul G Richardson; Sundar Jagannath; Robert Z Orlowski; Cynthia R Giver; David L Jaye; Dixil Francis; Sara Giusti; Claire Torre; Bart Barlogie; James R Berenson; Seema Singhal; David P Schenkein; Dixie-Lee W Esseltine; Jessica Anderson; Hugh Xiao; Leonard T Heffner; Kenneth C Anderson
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

Review 3.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 4.  Border between aplastic anemia and myelodysplastic syndrome.

Authors:  Hirohito Yamazaki; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

Review 5.  Thrombocytosis: too much of a good thing?

Authors:  Andrew I Schafer
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

6.  Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.

Authors:  Yu Seiki; Yumi Sasaki; Kohei Hosokawa; Chizuru Saito; Naomi Sugimori; Hirohito Yamazaki; Akiyoshi Takami; Shinji Nakao
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

7.  ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization.

Authors:  Roberta Bottega; Caterina Marconi; Michela Faleschini; Gabriele Baj; Claudia Cagioni; Alessandro Pecci; Tommaso Pippucci; Ugo Ramenghi; Simonetta Pardini; Loretta Ngu; Carlo Baronci; Shinji Kunishima; Carlo L Balduini; Marco Seri; Anna Savoia; Patrizia Noris
Journal:  Blood       Date:  2014-10-31       Impact factor: 22.113

8.  Bone marrow remodeling supports hematopoiesis in response to immune thrombocytopenia progression in mice.

Authors:  Oliver J Herd; Gulab Fatima Rani; James P Hewitson; Karen Hogg; Andrew P Stone; Nichola Cooper; David G Kent; Paul G Genever; Ian S Hitchcock
Journal:  Blood Adv       Date:  2021-12-14

Review 9.  The thrombopoietin receptor: revisiting the master regulator of platelet production.

Authors:  Ian S Hitchcock; Maximillian Hafer; Veena Sangkhae; Julie A Tucker
Journal:  Platelets       Date:  2021-06-07       Impact factor: 3.862

10.  Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy.

Authors:  Xu Zhang; Yajing Zhao; Xiaoqing Li; Panpan Han; Fangmiao Jing; Zhangyuan Kong; Hai Zhou; Jihua Qiu; Lizhen Li; Jun Peng; Ming Hou
Journal:  Oncotarget       Date:  2016-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.